Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Krascendo 2: Divarasib + Pembrolizumab in KRAS G12C-Mutated NSCLC
NCT06793215Phase 3Recruiting
- Sponsor
- Roche
- Start
- Oct 2025
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 28
01
Overview
A Phase 3 trial of divarasib in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Oct 2025; status: recruiting.
02
Drugs
divarasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06793215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06793215.